ERK
Extracellular signal regulated kinases
ERKs (Extracellular-signal-regulated kinases) are widely expressed protein kinase intracellular signalling molecules that are involved in functions including the regulation of meiosis, mitosis, and postmitotic functions in differentiated cells. Many different stimuli, including growth factors, cytokines, virus infection, ligands for heterotrimeric G protein-coupled receptors, transforming agents, and carcinogens, activate the ERK pathway. In the MAPK/ERK pathway, Ras activates c-Raf, followed by mitogen-activated protein kinase kinase (abbreviated as MKK, MEK, or MAP2K) and then MAPK1/2 (below). Ras is typically activated by growth hormones through receptor tyrosine kinases and GRB2/SOS, but may also receive other signals. ERKs are known to activate many transcription factors, such as ELK1, and some downstream protein kinases. Disruption of the ERK pathway is common in cancers, especially Ras, c-Raf and receptors such as HER2.
ERK Isoform Specific Products
All Product Categories
-
ERK Inhibitors
(762)
View all products
-
ERK Agonists
(10)
View all products
-
ERK Activators
(267)
View all products
-
ERK Modulators
(19)
View all products
-
ERK Chemical
(1)
View all products
-
ERK Inducers
(17)
View all products
-
ERK Degraders
(2)
View all products
-
ERK Controls
(3)
View all products
-
ERK Ligands
(2)
View all products
-
ERK Related Products (1167)
Related Products (1167)
-
Antibodies (22)
-
ERK Isoform Comparison
-
Sitagliptin-d4
0 ImagesCat. No.: HY-13749S2Synonyms: MK-0431-d4Sitagliptin-d4 (MK-0431-d4) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
-
Apoptosis inducer 55
0 ImagesCat. No.: HY-180226Apoptosis inducer 55 (Compound 10) is an Apoptosis inducer. Apoptosis inducer 55 induces rapid apoptosis via the intrinsic pathway. Apoptosis inducer 55 potently inhibits several signaling cascades including AKT, ERK1/2, STAT1, STAT3, and S6K. Apoptosis inducer 55 has anti-cancer activity against melanoma.
-
KRAS-IN-43
0 ImagesCat. No.: HY-176250KRAS-IN-43 (Compound 9) is a pan-KRAS inhibitor with IC50 values of 0.15 μM, 0.14 μM, and 0.47 μM against KRASG12V, KRASG12C and wild-type KRAS, respectively. KRAS-IN-43 disrupts the interaction between KRAS and cRAF, and inhibits ERK phosphorylation. KRAS-IN-43 is promising for research of KRAS mutation-related cancers (such as pancreatic cancer, colorectal cancer, and lung cancer).
-
DCZ19931
0 ImagesCat. No.: HY-152087CAS No.: 2789629-84-9DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling.
-
12(S)-HEPE
0 Images12 (S)-HEPE is an oxidation product of Eicosapentaenoic acid (HY-B0660). 12 (S)-HEPE activates p38α, GSKβ, CREB, and ERK1/2. 12 (S)-HEPE induces DNA synthesis. 12 (S)-HEPE leads to activation of the PI3K-mTORC2-Akt signaling pathway and translocation of Glut4 to the plasma membrane. 12 (S)-HEPE increases glucose uptake. 12 (S)-HEPE reduces body weight gain in HFD mice. 12 (S)-HEPE can be used in research on colorectal cancer, zymosan-induced peritonitis, diabetes, and obesity.
-
Acesulfame
0 ImagesAcesulfame is a synthetic sweetener. Long-term use of Acesulfame can affect cognitive function. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion.
-
Leupeptin Ac-LL
0 ImagesCat. No.: HY-18234BCAS No.: 24365-47-7Leupeptin Ac-LL is a broad-spectrum protease inhibitor. By inhibiting the activation of the PTEN/PI3K/Akt/NF-κB/ERK1/2/p38 signaling pathway, Leupeptin Ac-LL significantly reduces LPS-induced NO and ROS production, mitochondrial membrane potential hyperpolarization, phagocytic activity, pro-inflammatory cytokine release, and M1 polarization in mouse peritoneal macrophages, and reverses autophagic flux impairment. It also decreases Concanavalin A (HY-P2149)-induced proliferation index of mouse splenic lymphocytes and the Th1/IL-10 and Th2/IL-10 cytokine ratios, thereby modulating innate and adaptive immune responses. Leupeptin Ac-LL inhibits blood coagulation and tumorigenesis in mouse skin. Leupeptin Ac-LL can be used in research on chronic inflammatory diseases and skin tumorigenesis.
-
KRAS G12D-IN-36
0 ImagesCat. No.: HY-180920KRAS G12D-IN-36 (Compound 53a) is a highly selective and orally active KRAS-G12D inhibitor with an IC50 of 1.63 nM. KRAS G12D-IN-36 effectively inhibits p-ERK with an IC50 of 8.4 nM. KRAS G12D-IN-36 shows potent anti-proliferative activity against AsPC-1 cells. KRAS G12D-IN-36 can be used for research on pancreatic cancer.
-
TC6-D3
0 ImagesCat. No.: HY-P11928CAS No.: 3121532-43-9TC6-D3 is a proteolysis-resistant peptide and also a CC chemokine receptor 7 (CCR7) inhibitor, with a Kd value of 403 nM against mouse targets. TC6-D3 blocks the interaction between CCR7 and its ligands CCL19 and CCL21, and inhibits the activation of the ERK1/2 pathway. TC6-D3 reduces the migratory capacity of tumor cells in vitro. TC6-D3 inhibits tumor growth and lymph node metastasis in vivo. TC6-D3 restores T cell cytotoxicity, promotes CD8+ T cell infiltration, and enhances anti-tumor immune responses. TC6-D3 can be used in studies related to lymph node metastasis.
-
Laricitrin 3-rutinoside
0 ImagesCat. No.: HY-N7984CAS No.: 55481-90-8Synonyms: Laricitrin 3-O-rutinosideLaricitrin 3-rutinoside (Laricitrin 3-O-rutinoside) is a flavonol rutin. Laricitrin 3-rutinoside can be isolated from the fruits of Ginkgo biloba. Laricitrin 3-rutinoside inhibits ERK phosphorylation, reactive oxygen species (ROS) production, and matrix metalloproteinase-1 (MMP-1) secretion. Laricitrin 3-rutinoside inhibits Collagen degradation. Laricitrin 3-rutinoside reduces the secretion of proinflammatory cytokines interleukin 6 (IL-6) and interleukin 8 (IL-8). Laricitrin 3-rutinoside is applicable to research related to skin aging.
-
6'-BPANeuGc
0 ImagesCat. No.: HY-185659CAS No.: 1596134-78-96'-BPANeuGc is a CD22-targeting ligand. 6'-BPANeuGc suppresses BCR activation, recruits CD22 to B cell immunological synapses, initiates inhibitory signals, induces B cell apoptosis. 6'-BPANeuGc inhibits calcium flux, and inhibits Akt and Erk activation. 6'-BPANeuGc can be used for research on immune system diseases.
-
Gestodene-d7
0 ImagesCat. No.: HY-W753897Synonyms: SHB 331-d7; WL 70-d7Gestodene-d7 (SHB 331-d7; WL 70-d7) is the deuterated-labeled Gestodene (HY-B0110). Gestodene is an orally active synthetic progestogen compound of the 19-nortestosterone class. Gestodene binds with high affinity to the progesterone receptor, inhibits 5α-reductase, binds to androgen and aldosterone receptors, and inactivates CYP3A. Gestodene acts as a positive allosteric modulator of PAR1, enhances PAR1-mediated signaling pathways, and is capable of increasing the activation potency of PAR1-AP toward PAR1, thereby promoting ERK1/2 phosphorylation, receptor internalization, cell morphological changes, and human platelet aggregation. Gestodene and its A-ring reduced metabolites promote the proliferation, differentiation, and mineralization of neonatal rat osteoblasts. Gestodene itself has no binding capacity for estrogen receptors, and this osteogenic activity depends on intracellular metabolism to generate A-ring reduced products with estrogen-like agonistic activity. Gestodene is useful for research on diseases related to progesterone secretion and diseases related to thrombosis.
-
KZ-02
0 ImagesCat. No.: HY-185446CAS No.: 1801756-14-8KZ-02 is an orally active dual MEK1/Pim-1 kinase inhibitor, with an IC50 of 1.07 nM against MEK1 and an IC50 of 1.34 μM against Pim-1. KZ-02 reduces the phosphorylation levels of ERK and Cdc25C, and promotes the proteasomal degradation of Pim-1 protein. KZ-02 inhibits cancer cell growth and exerts anti-tumor effects. KZ-02 can be used in the research of colorectal cancer.
-
MARY1
0 ImagesCat. No.: HY-174306Purity: 99.46%MARY1 is a selective 5-HT2BR antagonist with an IC50 of 380 nM and a Ki of 764 nM (human 5-HT2BR). MARY1 induces renal mitochondrial biogenesis (MB) and enhances renal mitochondrial function by increasing mitochondrial respiratory capacity, mitochondrial protein levels, and mitochondrial number in renal proximal tubular cells (RPTCs). MARY1 induces MB through 5-HT2BR and dual PI3K/AKT and RAS/MEK/ERK cell signaling pathways in RPTCs. MARY1 can be used to study renal diseases associated with metabolic and mitochondrial dysfunction.
-
Hordenine hydrochloride (Standard)
0 ImagesSynonyms: Ordenina hydrochloride (Standard); Peyocactine hydrochloride (Standard)Hordenine hydrochloride (Standard) (Ordenina hydrochloride (Standard); Peyocactine hydrochloride (Standard)) is the analytical standard of Hordenine hydrochloride (HY-N0113B). This product is intended for research and analytical applications. Hordenine hydrochloride (Ordenina hydrochloride; Peyocactine hydrochloride) is a multifunctional alkaloid with oral activity and blood-brain barrier penetration. Hordenine hydrochloride inhibits LPS-induced phosphorylation of p38, JNK, ERK1/2, p65, IκB, and AKT, prevents p65 nuclear translocation, and suppresses inflammatory cytokines and mediators. Hordenine hydrochloride inhibits melanin synthesis in melanocytes and reconstructed epidermis. Hordenine hydrochloride activates the Wnt/β-catenin signaling pathway. Hordenine hydrochloride activates DRD2, acts as a D3R partial agonist, α2A-AR full agonist, and 5-HT2A-R antagonist, and inhibits SERT and DAT. Hordenine hydrochloride inhibits α-synuclein accumulation and ameliorates motor deficits in Parkinson's disease models. Hordenine hydrochloride limits alcohol intake, reduces relapse drinking behavior. Hordenine hydrochloride can be used for research on mastitis, skin pigmentation, acute lung injury, foodborne diseases, hair loss, Parkinson's disease, bacterial infections, and alcohol use disorder.
-
Raxofelast
0 ImagesCat. No.: HY-120485CAS No.: 128232-14-4Synonyms: IRFI-016Raxofelast (IRFI-016) is an antioxidant agent in various models of ischemia-reperfusion injury. Raxofelast has antiproliferative activity in H2O2-stimulated rat aortic smooth muscle cells. Raxofelast attenuates the activation of mitogen-activating protein kinase (MAPK), ERK kinase 1, 2 (MEK1,2) and protein kinase C (PKC) without affecting Ras expression.
-
Anti-inflammatory agent 116
0 ImagesCat. No.: HY-184324CAS No.: 2975573-18-1Anti-inflammatory agent 116 is an anti-inflammatory agent. Anti-inflammatory agent 116 inhibits the abnormal activation of the NF-κB/MAPK signaling pathway. Anti-inflammatory agent 116 binds to the p50 subunit and impairs the DNA-binding ability of the p65-p50 heterodimer. Anti-inflammatory agent 116 inhibits LPS-induced production of NO and MtROS, secretion of IL-1β and TNF-α, expression of iNOS and COX-2, phosphorylation of IKK, IκB, p65, p38, ERK and JNK, as well as nuclear translocation of p65. Anti-inflammatory agent 116 alleviates sepsis-associated acute liver injury in mice. Anti-inflammatory agent 116 can be used for the research of sepsis-associated acute liver injury.
